Evidence map›Paper›PMID 41400033›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Soft-Drug-Inspired MnSTF Nano-Adjuvant for Safe and Synergistic cGAS-STING Activation in Tumor Immunotherapy.

Guangfei Sun, Jiancheng Pan, Rui Li, Ruoxi Li, Ziyan Liu, Jinhui Wu, Tingsheng Lin, Yiqiao Hu, Ahu Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Guangfei SunState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Jiancheng PanState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Rui LiState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Ruoxi LiState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Ziyan LiuState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Jinhui WuState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.
Tingsheng LinDepartment of Urology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210093, P. R. China.
Yiqiao HuState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.ORCID https://orcid.org/0000-0002-3656-7143
Ahu YuanState Key Laboratory of Pharmaceutical Biotechnology, Medical School and School of Life Science, Nanjing University, Nanjing, 210093, P. R. China.

Funding

Logistics research projects BWS20J017National Natural Science Foundation of China 32371395National Natural Science Foundation of China 82473351Natural Science Foundation of Jiangsu Province BK20221445the National Key Research and Development Program of China 2022YFC3401600
6 · The paper itself

Abstract

The activation of the stimulator of interferon genes (STING) pathway is a cutting-edge strategy in tumor immunotherapy and has shown transformative potential in preclinical studies by inducing a type I interferon cascade and remodeling the tumor immune microenvironment. However, current STING agonists are limited by a narrow therapeutic window and substantial systemic toxicity, which significantly impedes their translational potential. To overcome these challenges, a novel self-assembling nanoadjuvant, MnSTF, grounded in the soft-drug design paradigm is designed. MnSTF is assembled through multidentate coordination between manganese ions (Mn

Indexed as

Adjuvants, ImmunologicImmunotherapyMembrane ProteinsNeoplasmsNucleotidyltransferasesAnimalsCell Line, TumorCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseHumansManganeseMiceSignal TransductionSTING ProteinTumor MicroenvironmentAdjuvants, ImmunologiccGAS protein, humanCyclic Guanosine Monophosphate-Adenosine Monophosphate SynthaseManganeseMembrane ProteinsNucleotidyltransferasesSTING1 protein, humanSting1 protein, mouseSTING Proteinantigen‐specific T cell responsenanoadjuvantsoft‐drug designSTING pathwaytumor immune microenvironment

Identifiers

PMID41400033
PMCPMC12904058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.